- Week 22-26 Jan, 2024, to incorporate comments by [[ISGlobal]]
- Week 22-26 Jan, 2024, to incorporate comments by [[ISGlobal]]
- [[ISGlobal]] convene virtual discussion on protocol to address emerging/outstanding comments
- [[ISGlobal]] convene virtual discussion on protocol to address emerging/outstanding comments
- IRB Submissions
- IRB Submissions
- ISGlobal responsible for submission of documents
- [[ISGlobal]] responsible for submission of documents
- Ghana submit by 1 Feb in advance of 7 Feb 2024 deadline (5 March as backup)
- Ghana submit by 1 Feb in advance of 7 Feb 2024 deadline (5 March as backup)
- [[GHS/RDD]] will notify of supporting documents needed for the IRB
- [[GHS/RDD]] will notify of supporting documents needed for the IRB
- Training - R&D/ISGlobal
- Training - R&D/ISGlobal
- Good Clinical Practice (can be GFDA or from different organization as long as not expired)
- Good Clinical Practice (can be GFDA or from different organization as long as not expired)
- Reference lab
- Reference lab
- Samples should be run on site (Kato Katz in the schools) and others in-country (ELISA dried blood spots for Strongyloides), with a lab in Accra still to be identified.
- Samples should be run on site (Kato Katz in the schools) and others in-country (ELISA dried blood spots for [[Strongyloides]]), with a lab in Accra still to be identified.
- Communication & Social mobilization - NTD Programme/RDD/Health Promotion/Mundo Sano
- Communication & Social mobilization - NTD Programme/ [[GHS/RDD]]/Health Promotion/Mundo Sano
- Frame messaging on why doing clinical trial as based on Trichuris burden – evidence for clinical trial most clear as albendazole is less effective and we have decent burden data; Reinforce messaging that will be a clinical trial, building on and using MDA architecture as much as possible
- Frame messaging on why doing clinical trial as based on [Trichuris] burden – evidence for clinical trial most clear as albendazole is less effective and we have decent burden data; Reinforce messaging that will be a clinical trial, building on and using MDA architecture as much as possible
- GHS to review external communications plan – Tuesday 19th
- GHS to review external communications plan – Tuesday 19th
- All/Mundo Sano facilitate
- All/Mundo Sano facilitate
- Circulate and review materials from past MDA and/or relevant trials from communications/social mobilization (GHS has already circulated)
- Circulate and review materials from past MDA and/or relevant trials from communications/social mobilization (GHS has already circulated)